Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Novartis Pharmaceuticals Corporation

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Secukinumab

            Therapeutic Area: Dermatology Product Name: Cosentyx

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial demonstrated significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Crizanlizumab

            Therapeutic Area: Genetic Disease Product Name: Adakveo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Data shows that nine out of ten people living with sickle cell disease experience one or more VOCs in a year, with a third of those crises leading to hospitalization, underscoring the significant unmet need among a vulnerable group of patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV gene therapy

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Recipient: Vedere Bio

            Deal Size: $280.0 million Upfront Cash: $150.0 million

            Deal Type: Acquisition October 29, 2020

            Details:

            Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NIS793,Spartalizumab,Gemcitabine

            Therapeutic Area: Oncology Product Name: NIS793

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: XOMA

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 28, 2020

            Details:

            The Phase 2 trial will assess the efficacy and safety of NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. The milestone payment is apart of an agreement signed between Xoma and Novartis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MP0420

            Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Molecular Partners

            Deal Size: $231.0 million Upfront Cash: $22.0 million

            Deal Type: Licensing Agreement October 28, 2020

            Details:

            Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Onasemnogene Abeparvovec,NAV AAV9 vector

            Therapeutic Area: Genetic Disease Product Name: Zolgensma

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Recipient: Regenxbio

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement October 27, 2020

            Details:

            REGENXBIO will receive a milestone payment of $80.0 million from Novartis AG based upon the achievement of $1.0 billion in cumulative net sales of Zolgensma. REGENXBIO expects to recognize this revenue in the third quarter of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iptacopan

            Therapeutic Area: Nephrology Product Name: LNP023

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Data presented at the ASN 2020 Annual Meeting shows that investigational iptacopan effectively and safely reduced proteinuria in patients with C3 glomerulopathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OP-1250,Ribociclib

            Therapeutic Area: Oncology Product Name: OP-1250

            Highest Development Status: Undisclosed Product Type: Small molecule

            Recipient: Olema Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 26, 2020

            Details:

            Novartis will evaluate OP-1250 and a selective ER degrader (SERD), in combination with each of Kisqali® (ribociclib) and Piqray® (alpelisib) in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), HER2 (-) breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iptacopan

            Therapeutic Area: Nephrology Product Name: LNP023

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the alternative complement pathway, which is involved in the underlying pathophysiology of IgA nephropathy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Branaplam

            Therapeutic Area: Genetic Disease Product Name: LMI070

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            In preclinical models, branaplam has been shown to reduce levels of mutant huntingtin protein. In addition, during the investigation of branaplam in spinal muscular atrophy (SMA), it was also observed to reduce huntingtin messenger RNA (mRNA) in SMA patients.

            PharmaCompass